NVE Corporation (NASDAQ: NVEC) extends Abbott supply pact through 2027 with higher pricing
Rhea-AI Filing Summary
NVE Corporation filed an amendment detailing a new change to its long-standing Supplier Partnering Agreement with Abbott’s subsidiary Pacesetter, Inc. Amendment No. 12, executed on December 12, 2025, extends the term of the agreement through December 31, 2027. NVE continues to supply products to Abbott under this agreement, which has been updated multiple times since its original January 3, 2006 signing.
The latest amendment also provides for increased pricing for 2026 and 2027, indicating that future product sales under the agreement will be at higher contractual prices during those years. The full text of Amendment No. 12 is included as Exhibit 10.6 with this amended report.
Positive
- None.
Negative
- None.
Insights
NVE extends a key Abbott supply agreement and raises future pricing.
NVE Corporation discloses Amendment No. 12 to its Supplier Partnering Agreement with Abbott’s Pacesetter, Inc. The amendment, executed on December 12, 2025, extends the contract term through December 31, 2027. NVE continues to supply products to Abbott under this framework, which has been periodically updated since the original January 3, 2006 agreement.
The amendment also increases pricing for calendar years 2026 and 2027. While no volumes or dollar amounts are stated, higher contracted pricing on these future shipments could influence revenue and margins depending on the scale of Abbott-related sales. The exhibit index notes that certain portions of the agreement are redacted as immaterial and competitively sensitive, which is standard for commercial terms of a major supply contract.
For investors, the key facts are the confirmed continuation of the Abbott relationship through the end of 2027 and the fact that prices will be higher in those two years. Subsequent disclosures in regular financial reports may show how this agreement contributes to segment revenue and profitability as the extended term and revised pricing take effect.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Amendment No. 11)
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| ||
( | (Zip Code) |
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading symbol(s) | Name of each exchange on which registered |
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
This Amendment No. 11 to Form 8-K is being filed to disclose Amendment No. 12 to our Supplier Partnering Agreement dated January 3, 2006 by and between Pacesetter, Inc., now a subsidiary of Abbott Laboratories (“Abbott”), and us, as amended by Amendment No. 1 to the Agreement dated September 6, 2007, Amendment No. 2 dated December 15, 2009, Amendment No. 3 dated September 13, 2010, Amendment No. 4 dated February 1, 2011, Amendment No. 5 dated April 20, 2016, Amendment No. 6 dated December 18, 2020, Amendment No. 7 dated April 30, 2021, Amendment No. 8 dated February 1, 2022, Amendment No. 9 dated January 20, 2023, Amendment No. 10 received on January 2, 2024, and Amendment No. 11 dated February 10, 2025. Amendment Nos. 1, 2, 3, 6, 7, 9, 10, and 11 were superseded by subsequent amendments.
Item 1.01. Entry into a Material Definitive Agreement.
General Information
We supply products to Abbott under the Supplier Partnering Agreement as amended.
Description of the Terms and Conditions of the Amendment
Amendment No. 12 to the Supplier Partnering Agreement was executed on December 12, 2025 extending the Agreement term through December 31, 2027 and increasing pricing for 2026 and 2027. The Amendment is filed as Exhibit 10.6 to this Current Report on Form 8-K/A.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date December 17, 2025 | NVE CORPORATION
|
|
3
INDEX TO EXHIBITS
Exhibit # | Description |
10.1 | Indemnification Agreement by and between Pacesetter, Inc., a St. Jude Medical Company, d.b.a. St. Jude Medical Cardiac Rhythm Management Division, and the company (incorporated by reference to the Form 8-K filed September 27, 2005). |
10.2+ | Supplier Partnering Agreement by and between St. Jude and the company (incorporated by reference to the Form 8-K filed January 4, 2006). |
10.3 | Amendment No. 4 to Supplier Partnering Agreement between St. Jude and the company (incorporated by reference to the Form 8-K/A filed February 7, 2011). |
10.4 | Amendment No. 5 to Supplier Partnering Agreement between St. Jude and the company (incorporated by reference to the Form 8-K/A filed April 21, 2016). |
10.5* | Amendment No. 8 to Supplier Partnering Agreement between Abbott and the company (incorporated by reference to the Form 8-K/A filed February 2, 2022). |
10.6* | Amendment No. 12 to Supplier Partnering Agreement between Abbott and the company (filed with this Current Report on Form 8-K/A).
|
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
+Confidential portions of this exhibit were deleted and filed separately with the SEC under a request for confidential treatment pursuant to Rule 24b-2 or Rule 406.
*Certain confidential portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause us competitive harm if publicly disclosed. We agree to furnish supplementally an unredacted copy of the exhibit to the Securities and Exchange Commission on its request.
4
FAQ
What did NVE Corporation (NVEC) disclose in this 8-K/A amendment?
NVE Corporation disclosed Amendment No. 12 to its Supplier Partnering Agreement with Pacesetter, Inc., a subsidiary of Abbott Laboratories. The amendment extends the agreement and adjusts future pricing, and is filed as Exhibit 10.6 with this amended report.
How long is NVE Corporations supply agreement with Abbott now extended?
Amendment No. 12 extends NVE Corporations Supplier Partnering Agreement with Abbotts Pacesetter, Inc. through December 31, 2027, providing visibility on the relationship for the next several years.
Does Amendment No. 12 change pricing under NVE Corporations agreement with Abbott?
Yes. The filing states that Amendment No. 12 increases pricing for 2026 and 2027 under the Supplier Partnering Agreement between NVE Corporation and Abbotts Pacesetter, Inc.
What is the relationship between NVE Corporation (NVEC) and Abbott in this agreement?
NVE Corporation supplies products to Abbott under a long-term Supplier Partnering Agreement. The agreement began on January 3, 2006 and has been modified multiple times, including the newly disclosed Amendment No. 12.
Where can investors find the full text of Amendment No. 12 for NVE Corporation?
The full text of Amendment No. 12 to the Supplier Partnering Agreement between NVE Corporation and Abbott is filed as Exhibit 10.6 with this amended current report.
Why are some portions of NVE Corporations agreement exhibits with Abbott redacted?
The filing states that certain confidential portions of the Supplier Partnering Agreement amendments have been redacted because the omitted information is not material and could cause competitive harm if publicly disclosed. An unredacted copy can be provided to the SEC upon request.
